PMID- 20470221
OWN - NLM
STAT- MEDLINE
DCOM- 20100927
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 51
IP  - 6
DP  - 2010 Jun
TI  - Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through 
      down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous 
      leukemia cell line.
PG  - 1090-7
LID - 10.3109/10428191003746315 [doi]
AB  - The bone marrow microenvironment protects leukemia cells from drug-induced 
      damage, and cell adhesion-mediated drug resistance (CAM-DR) is the main obstacle 
      for the eradication of bone marrow minimal residual disease. In this study, we 
      evaluated the survival response of K562 cells co-cultured with bone marrow 
      stromal cells (BMSCs) derived from patients with chronic myelogenous leukemia 
      (CML). Co-cultured K562 cells had a survival advantage after exposure to 
      cytotoxic drugs compared to suspended K562 cells, but there was no survival 
      difference between the two groups following exposure to As(2)O(3). The 
      cytotoxicity of As(2)O(3) combined with cytotoxic drugs had an additive effect in 
      the suspension group and a synergistic effect in the co-cultured group. Similar 
      apoptotic responses were found using flow cytometry assays. As(2)O(3) treatment 
      caused a dose dependent reduction of the adhesion ability of K562 cells to BMSCs, 
      and Western blot analysis revealed that the treatment of K562 cells with 
      As(2)O(3) led to down-regulation of beta(1)-integrin.
FAU - Guo-Bao, Wang
AU  - Guo-Bao W
AD  - State Key Laboratory of Oncology in South China, Guangzhou, PR China.
FAU - Xiao-Qin, Chen
AU  - Xiao-Qin C
FAU - Qi-Rong, Geng
AU  - Qi-Rong G
FAU - Jie, Li
AU  - Jie L
FAU - Gui-Nan, Lin
AU  - Gui-Nan L
FAU - Yue, Lu
AU  - Yue L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Arsenicals)
RN  - 0 (Integrin beta1)
RN  - 0 (Oxides)
RN  - 04079A1RDZ (Cytarabine)
RN  - S7V92P67HO (Arsenic Trioxide)
RN  - ZS7284E0ZP (Daunorubicin)
SB  - IM
MH  - Antineoplastic Agents/pharmacology
MH  - Apoptosis/drug effects
MH  - Arsenic Trioxide
MH  - Arsenicals/*pharmacology
MH  - Blotting, Western
MH  - Bone Marrow Cells/pathology
MH  - Cell Adhesion/drug effects
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Coculture Techniques
MH  - Cytarabine/pharmacology
MH  - Daunorubicin/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Down-Regulation/drug effects
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Drug Synergism
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Integrin beta1/*metabolism
MH  - K562 Cells
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood/pathology
MH  - Oxides/*pharmacology
MH  - Stromal Cells/drug effects/metabolism/pathology
EDAT- 2010/05/18 06:00
MHDA- 2010/09/29 06:00
CRDT- 2010/05/18 06:00
PHST- 2010/05/18 06:00 [entrez]
PHST- 2010/05/18 06:00 [pubmed]
PHST- 2010/09/29 06:00 [medline]
AID - 10.3109/10428191003746315 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2010 Jun;51(6):1090-7. doi: 10.3109/10428191003746315.